Locus-specific LOH, which can be determined from already existing DNA-based FFPE tumor testing pipelines remains a clinically promising and more cost-effective means of predicting therapy response in germline BRCA1 and BRCA2 carriers. This evidence concerns the gene BRCA1 and neoplasm.